{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:59:50Z","timestamp":1760237990590,"version":"build-2065373602"},"reference-count":138,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ecl.2021.12.006","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T10:02:44Z","timestamp":1651658564000},"page":"265-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thyroid Dysfunction from Treatments for Solid Organ Cancers"],"prefix":"10.1016","volume":"51","author":[{"given":"Anupam","family":"Kotwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald S.A.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib2","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1530\/EC-20-0489","article-title":"Endocrine toxicity of cancer immunotherapy: clinical challenges","volume":"10","author":"Anderson","year":"2021","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib6","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.006_bib7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2021.12.006_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2021.01.017","article-title":"Thyroid immune-related adverse events in patients with cancer treated with anti-PD1\/anti-CTLA4 immune checkpoint inhibitor combination: clinical course and outcomes","author":"Lui","year":"2021","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.006_bib9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2021.12.006_bib10","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","author":"Muir","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MED.0000000000000652","article-title":"Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib15","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes Aug"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib18","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol Nov"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib19","first-page":"e8602","article-title":"A\u00a0rare case of immune-mediated primary adrenal insufficiency with cytotoxic T-lymphocyte antigen-4 inhibitor ipilimumab in metastatic melanoma of lung and neck of unknown primary","volume":"12","author":"Gaballa","year":"2020","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/OP.20.00781","article-title":"Adrenal insufficiency from immune checkpoint inhibitors masquerading as sepsis","volume":"17","author":"Abdallah","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.mayocpiqo.2020.07.006","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","journal-title":"Mayo Clinic Proc Innov Qual Outcomes"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib23","doi-asserted-by":"crossref","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.006_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid Jul"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.006_bib26","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12022-019-9579-2","article-title":"Pembrolizumab-induced thyroiditis","volume":"30","author":"Imblum","year":"2019","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ecl.2021.12.006_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","author":"Luongo","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.006_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ecl.2021.12.006_bib31","doi-asserted-by":"crossref","first-page":"107296","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib33","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti\u2013PD-1\u2013induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1210\/jcem-71-3-661","article-title":"Antithyroid peroxidase autoantibodies in thyroid diseases","volume":"71","author":"Mariotti","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2265.2003.01633.x","article-title":"Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency","volume":"58","author":"Pedersen","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib38","first-page":"2140","article-title":"Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade","volume":"18","author":"Sakakida","year":"2019","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib40","first-page":"41","article-title":"CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population","volume":"80","author":"Yanagawa","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2265.1997.1710996.x","article-title":"A\u00a0CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism","volume":"46","author":"Kotsa","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.006_bib42","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"593","key":"10.1016\/j.ecl.2021.12.006_bib43","doi-asserted-by":"crossref","first-page":"eabb7495","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T\u00a0cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Translational Med"},{"issue":"18","key":"10.1016\/j.ecl.2021.12.006_bib44","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","article-title":"Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ecl.2021.12.006_bib45","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2021.0165","article-title":"Distinct cytokine signatures in thyroiditis induced by PD-1 or CTLA-4 blockade: insights from a new mouse model","author":"Ippolito","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2021.12.006_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ecl.2021.12.006_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214603","article-title":"A\u00a0rare case of thyroid storm","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ecl.2021.12.006_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000464285","article-title":"Tremelimumab-induced Graves hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ecl.2021.12.006_bib51","first-page":"2087525","article-title":"Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib52","first-page":"13","article-title":"Graves' disease during immune checkpoint inhibitor therapy (a case series and literature review)","author":"Peiffert","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib53","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"17","key":"10.1016\/j.ecl.2021.12.006_bib54","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib55","first-page":"1111","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer Mar 15"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib56","first-page":"483","article-title":"Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy","volume":"64","author":"Brilli","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.ecl.2021.12.006_bib57","doi-asserted-by":"crossref","DOI":"10.1097\/MED.0000000000000664","article-title":"Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers","author":"Kotwal","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","article-title":"Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors","volume":"70","author":"Lima Ferreira","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib59","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","article-title":"Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes","volume":"64","author":"Peir\u00f3","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib60","doi-asserted-by":"crossref","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2018","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4158\/EP-2019-0244","article-title":"Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review","volume":"26","author":"Al Mushref","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2021.12.006_bib64","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib65","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2021.12.006_bib66","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.006_bib67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"9940","key":"10.1016\/j.ecl.2021.12.006_bib69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ecl.2021.12.006_bib70","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.006_bib71","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib73","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"The J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ecl.2021.12.006_bib75","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"The J Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.ecl.2021.12.006_bib76","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1308893","article-title":"Thyroid hormone inactivation in gastrointestinal stromal tumors","volume":"370","author":"Maynard","year":"2014","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib77","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"The J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib78","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2016-4025","article-title":"Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma","volume":"102","author":"Beukhof","year":"2017","journal-title":"The J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib79","doi-asserted-by":"crossref","first-page":"e0147048","DOI":"10.1371\/journal.pone.0147048","article-title":"Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses","volume":"11","author":"Shu","year":"2016","journal-title":"PLOS ONE"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"issue":"9807","key":"10.1016\/j.ecl.2021.12.006_bib82","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ecl.2021.12.006_bib83","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"New Engl J Med"},{"issue":"10126","key":"10.1016\/j.ecl.2021.12.006_bib85","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib86","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A\u00a0randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: Final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9829","key":"10.1016\/j.ecl.2021.12.006_bib87","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"9544","key":"10.1016\/j.ecl.2021.12.006_bib88","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New Engl J Med"},{"issue":"9863","key":"10.1016\/j.ecl.2021.12.006_bib90","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.ecl.2021.12.006_bib95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1089\/thy.2007.0104","article-title":"Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report","volume":"17","author":"Faris","year":"2007","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib96","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"Grossmann","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.006_bib97","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/14737140.2014.929501","article-title":"Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther Sep"},{"issue":"11","key":"10.1016\/j.ecl.2021.12.006_bib98","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.006_bib99","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med Nov 7"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid"},{"issue":"26","key":"10.1016\/j.ecl.2021.12.006_bib101","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib102","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ecl.2021.12.006_bib103","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2021.12.006_bib104","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib105","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.urolonc.2010.07.015","article-title":"The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study","volume":"30","author":"Baldazzi","year":"2012","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib106","first-page":"3177","article-title":"Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy","volume":"34","author":"KUST","year":"2014","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib107","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jjco\/hyv045","article-title":"Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients","volume":"45","author":"Akaza","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib108","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.clgc.2014.11.002","article-title":"Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"13","author":"Bailey","year":"2015","journal-title":"Clin Genitourinary Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib109","first-page":"230","article-title":"Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?","volume":"28","author":"Bozkurt","year":"2016","journal-title":"J\u00a0Chemother"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.006_bib110","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1089\/thy.2016.0159","article-title":"Hypothyroidism and thyroid autoimmunity as a prognostic biomarker of better response in metastatic cancer long-term survivors treated with sunitinib","volume":"26","author":"Pani","year":"2016","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib111","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12885-019-5610-8","article-title":"\u0399mpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer","volume":"19","author":"Vasileiadis","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib112","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib113","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib114","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CAD.0000000000000439","article-title":"Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors","volume":"28","author":"Iacovelli","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib115","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/annonc\/mdr275","article-title":"Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?","volume":"23","author":"Sabatier","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13104-016-1895-8","article-title":"The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study","volume":"9","author":"Miyake","year":"2016","journal-title":"BMC Res Notes"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib117","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.clgc.2019.10.003","article-title":"On-target toxicities predictive of survival in metastatic renal cell carcinoma (mRCC) treated with sunitinib: a multicenter retrospective study","volume":"18","author":"Bolzacchini","year":"2020","journal-title":"Clin Genitourinary Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2021.12.006_bib118","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000499089","article-title":"Axitinib-induced hypothyroidism as a predictor of long-term survival in patients with metastatic renal cell carcinoma","volume":"102","author":"Takada","year":"2019","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12032-018-1239-8","article-title":"The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Kucharz","year":"2019","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib120","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1111\/ajco.12983","article-title":"A\u00a0novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib","volume":"14","author":"Chu","year":"2018","journal-title":"Asia-Pacific J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2021.12.006_bib121","first-page":"12","article-title":"Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy","author":"Shomura","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib122","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3892\/ol.2020.11758","article-title":"Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: a multicenter cohort study using data mining analysis","volume":"20","author":"Shimose","year":"2020","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40801-020-00179-7","article-title":"Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study","volume":"7","author":"Ohki","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"9","key":"10.1016\/j.ecl.2021.12.006_bib124","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1507\/endocrj.EJ19-0140","article-title":"Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma","volume":"66","author":"Koizumi","year":"2019","journal-title":"Endocr J"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2021.12.006_bib125","doi-asserted-by":"crossref","first-page":"39s","DOI":"10.2967\/jnumed.116.186833","article-title":"Norepinephrine transporter as a target for imaging and therapy","volume":"58","author":"Pandit-Taskar","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib126","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.12.006_bib127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.25200","article-title":"Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy","volume":"62","author":"Streby","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid Jun"},{"issue":"1091","key":"10.1016\/j.ecl.2021.12.006_bib129","doi-asserted-by":"crossref","first-page":"20180103","DOI":"10.1259\/bjr.20180103","article-title":"MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies","volume":"91","author":"Agrawal","year":"2018","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib130","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib131","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12149-015-0960-z","article-title":"Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors: Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, the Japanese Society of Nuclear Medicine","volume":"29","author":"Kinuya","year":"2015","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1016\/j.ecl.2021.12.006_bib132","doi-asserted-by":"crossref","first-page":"379","DOI":"10.32641\/rchped.v91i3.1237","article-title":"[Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma]","volume":"91","author":"Garrido Maga\u00f1a","year":"2020","journal-title":"Rev Chil Pediatr"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib133","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.bjc.6694223","article-title":"131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients","volume":"81","author":"Garaventa","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ecl.2021.12.006_bib134","doi-asserted-by":"crossref","first-page":"647361","DOI":"10.3389\/fonc.2021.647361","article-title":"Factors modifying outcome after MIBG therapy in children with neuroblastoma-a national retrospective study","volume":"11","author":"Ussowicz","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2021.12.006_bib135","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/cncr.10447","article-title":"High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma","volume":"94","author":"van Santen","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib136","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.22767","article-title":"Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma","volume":"56","author":"Quach","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib137","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.11523","article-title":"Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma","volume":"98","author":"van Santen","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2021.12.006_bib138","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00259-014-2967-4","article-title":"Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma","volume":"42","author":"Clement","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ecl.2021.12.006_bib139","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/thy.2011.0464","article-title":"Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases","volume":"22","author":"van Santen","year":"2012","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib141","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2021.12.006_bib142","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2021.12.006_bib143","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New Engl J Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:55Z","timestamp":1760176015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852921001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0889852921001298"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.12.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Dysfunction from Treatments for Solid Organ Cancers","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}